Unidad Clínica de Cáncer Familiar

Miguel Urioste Jefe de Unidad Clínica
T +34 917328000 (Ext 3315)
murioste@cnio.es

Becarios Pre-Doctorales

Laura Pena

Técnicos de Laboratorio

Verónica García
Fátima Mercadillo

Lynch syndrome is a very complex entity associated with high risks for a wide variety of malignancies, including colorectal, endometrial, ovarian, gastric, urinary tract, pancreatic, biliary, small intestinal, prostatic, and brain cancers. Until now, the malignancies developed in people with Lynch syndrome were treated exactly in the same way as their sporadic counterparts. However, recent therapeutic advances in the immunologic effects of microsatellite instability (MSI), the hallmark of Lynch syndrome associated tumours, have resulted in important changes in the treatment of these patients.

MSI, by definition, is characterised by the somatic accumulation of mutations, which subsequently produce potentially antigenic frameshift neopeptides that account for the infiltrating lymphocyte reaction classically observed in Lynch-associated tumours. The recent emergence of immune checkpoint inhibitors that work on the patients’ own immune system has led to the use of this underlying biological characteristic to advance in the treatment of Lynch syndrome-associated tumours.

The Familial Cancer Clinical Unit (FCCU) is not only committed to screening blood samples with the aim of identifying germline mutations, but also to analysing tumour samples to determine their microsatellite status. Both findings play a critical role in the understanding of the molecular drivers of malignancy and the implementation of innovative precision-based therapies.

Publicaciones

Perea J, García JL, Corchete L, Lumbreras E, Arriba M, Rueda D, Tapial S, Pérez J, Vieiro V, Rodríguez Y, Brandáriz L, García-Arranz M, García-Olmo D, Goel A, Urioste M, González Sarmiento R (2019). Redefining synchronous colorectal cancers based on tumor clonality. Int J Cancer 144, 1596-1608.
Álvaro E, Cano JM, García JL, Brandáriz L, Olmedillas-López S, Arriba M, Rueda D, Rodríguez Y, Cañete Á, Arribas J, Inglada-Pérez L, Pérez J, Gómez C, García-Arranz M, García-Olmo D, Goel A, Urioste M, González-Sarmiento R, Perea J (2019). Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer. Int J Mol Sci (in press).
Arriba M, Sánchez C, Vivas A, Nutu OA, Rueda D, Tapial S, Rodríguez Y, Brandáriz L, García JL, García-Olmo D, Goel A, González-Sarmiento R, Urioste M, Perea J (2019). Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer. PLoS One (in press).
Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Triviño JC, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Rodríguez Moreno JF, Fernández Aramburo A, López C, Maroto P, Sastre J, Juan Fita MJ, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, Autran AM, Benítez J (2018). Whole Exome Sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. Int J Cancer 143, 1954-1962.
Bellido F, Sowada N, Mur P, Lázaro C, Pons T, Valdés-Mas R, Pineda M, Aiza G, Iglesias S, Soto JL, Urioste M, Caldés T, Balbín M, Blay P, Rueda D, Durán M, Valencia A, Moreno V, Brunet J, Blanco I, Navarro M, Calin GA, Borck G, Puente XS, Capellá G, Valle L (2018). Association between germline mutations in BRF1, a subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. Gastroenterology 154, 181-194.
Mur P, De Voer RM, Olivera-Salguero R, Rodríguez-Perales S, Pons T, Setién F, Aiza G, Valdés-Mas R, Bertini A, Pineda M, Vreede L, Navarro M, Iglesias S, González S, Brunet J, Valencia A, Esteller M, Lázaro C, Kops GJPL, Urioste M, Puente XS, Capellá G, Valle L (2018). Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis. Mol Can 17, 23.
Alonso N, Cañueto J, Ciria S, Bueno E, Palacios-Alvarez I, Alegre M, Badenas C, Barreiro A, Pena L, Maldonado C, Nespeira-Jato MV, Peña-Penabad C, Azon A, Gavrilova M, Ferrer I, Sanmartin O, Robles L, Hernandez-Martin A, Urioste M, Puig S, Puig L, Gonzalez-Sarmiento R (2018). Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome. Brit J Dermatol 178, 198-206.
Tapial S, Rueda D, Arriba M, Luis García J, Brandáriz L, Pérez J, Rodríguez Y, García-Olmo D, González-Sarmiento R, Urioste M, Perea J (2018). Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system’. Br J Cancer 118, E3.
Mur P, Jemth AS, Bevc L, Amaral N, Navarro M, Valdés-Mas R, Pons T, Aiza G, Urioste M, Valencia A, Lázaro C, Moreno V, Puente XS, Stenmark P, Warpman-Berglund U, Capellá G, Helleday T, Valle L (2018). Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis. Hum Mutat 39, 1214-1225.
Brandariz L, Arriba M, García JL, Cano JM, Rueda D, Rubio E, Rodríguez Y, Pérez J, Vivas A, Sánchez C, Tapial S, Pena L, García-Arranz M, García-Olmo D, Urioste M, González-Sarmiento R, Perea J (2018). Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location. Oncotarget 9, 15302-15311.
Pena-Couso L, Perea J, Melo S, Mercadillo F, Figueiredo J, Sanches JM, Sánchez-Ruiz A, Robles L, Seruca R, Urioste M (2018). Clinical and functional characterization of the CDH1 germline variant c.1679C>G in three unrelated families with hereditary diffuse gastric cancer. Eur J Hum Genet 26, 1348-1353.
Gayarre J, Martín-Gimeno P, Osorio A, Paumard B, Barroso A, Fernández V, de la Hoya M, Rojo A, Caldés T, Palacios J, Urioste M, Benítez J, García MJ (2017). Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.. Br J Cancer 117, 1048-1062.
Calvete O, Garcia-Pavia P, Domínguez F, Bougeard G, Kunze K, Braeuninger A, Teule A, Lasa A, Ramón Y Cajal T, Llort G, Fernández V, Lázaro C, Urioste M, Benitez J. (2017). The wide spectrum of POT1 gene variants correlates with multiple cancer types.. Eur J Hum Genet 25, 1278-1281.
Tavera-Tapia A, Pérez-Cabornero L, Macías JA, Ceballos MI, Roncador G, de la Hoya M, Barroso A, Felipe-Ponce V, Serrano-Blanch R, Hinojo C, Miramar-Gallart MD, Urioste M, Caldés T, Santillan-Garzón S, Benitez J, Osorio A (2017). Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.. Breast Cancer Res Treat 161, 117-134.
Benítez-Buelga C, Baquero JM, Vacklova T, Fernández V, Martín P, Inglada-Perez L, Urioste M, Osorio A, Benítez J (2017). Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers. Oncotarget 8, 114626-114636. Open Access
Perea J, García JL, Pérez J, Rueda D, Arriba M, Rodríguez Y, Urioste M, González-Sarmiento R (2017). NOMO-1 gene is deleted in early-onset colorectal cancer. Oncotarget 8, 24429-24436.
Arriba M, Sánchez R, Rueda D, Gómez L, García JL, Rodríguez Y, Díaz D, Pajares JA, Pérez J, Urioste M, González-Sarmiento R, Perea J (2017). Toward a Molecular Classification of Synchronous Colorectal Cancer: Clinical and Molecular Characterization.. Clin Colorectal Cancer 16, 31-37.
Perea J, Arriba M, Rodríguez Y, Rueda D, García JL, Pérez J, González-Sarmiento R, Urioste M (2017). Frequency and impact of KRAS mutation in early onset colorectal cancer.. Hum Pathol 61, 221-222.
Benitez-Buelga C, Vaclová T, Ferreira S, Urioste M, Inglada-Perez L, Soberón N, Blasco MA, Osorio A, Benitez J (2016). Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.. Oncotarget 7, 25815-25825.
Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A (2016). Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.. Hum Mol Genet 25, 5287-5299.
Kastrinos F, Ojha RP, Leenen C, Alvero C, Mercado RC, Balmaña J, Valenzuela I, Balaguer F, Green R, Lindor NM, Thibodeau SN, Newcomb P, Win AK, Jenkins M, Buchanan DD, Bertario L, Sala P, Hampel H, Syngal S, Steyerberg EW; Lynch Syndrome prediction model validation study group (2016). Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.. J Natl Cancer I 108, djv308.
Perea J, Arriba M, Rueda D, Sánchez R, García JL, Pérez J, Rodríguez Y, González-Sarmiento R, Urioste M (2016). Comment on ‘Wild-type APC prediction of poor prognosis in microsatellite-stable proximal colorectal cancer differs according to the age of onset’.. Br J Cancer 114, e7.
Mur P, Sánchez-Cuartielles E, Aussó S, Aiza G, Valdés-Mas R, Pineda M, Navarro M, Brunet J, Urioste M, Lázaro C, Moreno V, Capellá G, Puente XS, Valle L (2016). Scarce evidence of the causal role of germline mutations in UNC5C in hereditary colorectal cancer and polyposis.. Sci Rep 6, 20697.
Arriba M, García JL, Rueda D, Pérez J, Brandariz L, Nutu OA, Alonso L, Rodríguez Y, Urioste M, González-Sarmiento R, Perea J (2016). Unsupervised Analysis of Array Comparative Genomic Hybridization Data from Early-Onset Colorectal Cancer Reveals Equivalence with Molecular Classification and Phenotypes.. Neoplasia 19, 28-34.
Calvete O, Martinez P, Garcia-Pavia P, Benitez-Buelga C, Paumard-Hernández B, Fernandez V, Dominguez F, Salas C, Romero-Laorden N, Garcia-Donas J, Carrillo J, Perona R, Triviño JC, Andrés R, Cano JM, Rivera B, Alonso-Pulpon L, Setien F, Esteller M, Rodriguez-Perales S, Bougeard G, Frebourg T, Urioste M, Blasco MA, Benítez J. (2015). A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.. Nat Communications 6, 8383.
Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J (2015). Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.. Breast Cancer Res Treat 149, 385-394.
Kamieniak MM, Rico D, Milne RL, Muñoz-Repeto I, Ibáñez K, Grillo MA, Domingo S, Borrego S, Cazorla A, García-Bueno JM, Hernando S, García-Donas J, Hernández-Agudo E, Ramón y Cajal T, Robles-Díaz L, Márquez-Rodas I, Cusidó M, Sáez R, Lacambra-Calvet C, Osorio A, Urioste M, Cigudosa JC, Paz-Ares L, Palacios J, Benítez J , García MJ (2015). Deletion At 6Q24.2-26 Predicts Longer Survival Of High-Grade Serous Epithelial Ovarian Cancer Patients.. Mol Oncol 9, 422-436.
Arriba M, García JL, Inglada-Pérez L, Rueda D, Osorio I, Rodríguez Y, Álvaro E, Sánchez R, Fernández T, Pérez J, Hernández JM, Benítez J, González-Sarmiento R, Urioste M, Perea J (2015). DNA copy number profiling reveals different patterns of chromosomal instability within colorectal cancer according to the age of onset.. Mol Carcinogen (in press).
Sánchez-Tomé E, Rivera B, Perea J, Pita G, Rueda D, Mercadillo F, Canal A, Gonzalez-Neira A, Benitez J, Urioste M (2015). Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X.. J Gastroenterol 50, 657-666.
Perea J, Cano JM, Rueda D, García JL, Inglada L, Osorio I, Arriba M, Pérez J, Gaspar M, Fernández-Miguel T, Rodríguez Y, Benítez J, González-Sarmiento R, Urioste M (2015). Classifying early-onset colorectal cancer according to tumor location: new potential subcategories to explore.. Am J Cancer Res 5, 2308-2313.
Vaclová T, Gómez-López G, Setién F, García-Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Benítez J, Osorio A (2015). Impaired DNA repair capacity and gene expression indicate haploinsufficiency in healthy heterozygous BRCA1 mutation carriers.. Breast Cancer Res Treat 152, 271-282.
Cascón A, Comino-Méndez I, Currás-Freixes M, de Cubas AA, Contreras L, Richter S, Peitzsch M, Mancikova V, Inglada-Pérez L, Pérez-Barrios A, Calatayud M, Azriel S, Villar-Vicente R, Aller J, Setién F, Moran S, Garcia JF, Río-Machín A, Letón R, Gómez-Graña Á, Apellániz-Ruiz M, Roncador G, Esteller M, Rodríguez-Antona C, Satrústegui J, Eisenhofer G, Urioste M, Robledo M (2015). Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene.. J Natl Cancer I 107, djv053.
Seguí N, Mina LB, Lázaro C, Sanz-Pamplona R, Pons T, Navarro M, Bellido F, López-Doriga A, Valdés-Mas R, Pineda M, Guinó E, Vidal A, Soto JL, Caldés T, Durán M, Urioste M, Rueda D, Brunet J, Balbín M, Blay P, Iglesias S, Garré P, Lastra E, Sánchez-Heras AB, Valencia A, Moreno V, Pujana MÁ, Villanueva A, Blanco I, Capellá G, Surrallés J, Puente XS, Valle L (2015). Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair.. Gastroenterology 149, 563-566.
Bellido F, Pineda M, Aiza G, Valdés-Mas R, Navarro M, Puente DA, Pons T, González S, Iglesias S, Darder E, Piñol V, Soto JL, Valencia A, Blanco I, Urioste M, Brunet J, Lázaro C, Capellá G, Puente XS, Valle L, (2015). POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.. Genet Med 18, 325-342.
Cabral de Almeida Cardoso L, Rodriguez-Laguna L, Del Carmen Crespo M, Vallespín E, Palomares-Bralo M, Martin-Arenas R, Rueda-Arenas I, Silvestre de Faria PA; GT-CSGP Working Group, García-Miguel P, Lapunzina P, Regla Vargas F, Seuanez HN, Martínez-Glez V (2015). Array CGH Analysis of Paired Blood and Tumor Samples from Patients with Sporadic Wilms Tumor.. PLoS ONE 10, e0136812.
Perea J, Rueda D, Canal A, Rodríguez Y, Alvaro E, Osorio I, Alegre C, Rivera B, Martínez J, Benítez J, Urioste M (2014). Age at Onset Should Be a Major Criterion for Subclassification of Colorectal Cancer.. J Mol Diagn 16, 116-126.
Rivera B, Perea J, Sánchez E, Villapún M, Sánchez-Tomé E, Mercadillo F, Robledo M, Benítez J, Urioste M (2014). A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia.. Eur J Hum Genet 22, 423-426.
Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ (2013). DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.. Br J Cancer 108, 1732-1742.